STAT+: Novo underwhelmed by drug it once fought Pfizer for

STAT PlusNewsletterThe Readout Novo underwhelmed by drug it once fought Pfizer for Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 8, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Gene therapies can now cure disease, but America still hasn’t figured out how to pay for them. Is there a better way? Also, Novo executives are downplaying a once-coveted obesity drug, Incyte is making a $2 billion blood disease bet, and new data suggest Boehringer’s obesity contender may struggle to stand out in an increasingly crowded market.Advertisement The need-to-know this morning Roche is partnering with Nurix Therapeutics to co-develop an experimental antibody treatment that works by degrading, or eliminating, a protein called BTK that is associated with blood cancer and other diseases. Treeline Biosciences, the developer of early-stage cancer medicines co-founded by biotech entrepreneur Josh Bilenker, is going public via a reverse merger with Standard BioTools. Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 8, 2026 STAT Plus: J&J spends $1 billion to enter KRAS race for cancer treatments Biotech June 8, 2026 STAT Plus: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate Advertisement Opinions+ June 8, 2026 $2 million gene therapy cures require a financing model Pharma June 6, 2026 STAT Plus: Lilly shares safety, tolerability data on its next-gen obesity drug Pharma June 6, 2026 STAT Plus: Detailed data show Pfizer’s monthly obesity drug continues to show potential Subscriber Picks